Mitf-Signal Responsive Transcription in Osteoclasts

破骨细胞中的 Mitf 信号响应转录

基本信息

  • 批准号:
    6877601
  • 负责人:
  • 金额:
    $ 29.92万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2005
  • 资助国家:
    美国
  • 起止时间:
    2005-03-01 至 2009-12-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Mitf is a helix-loop-helix transcription factor whose mutation produces severe osteopetrosis in multiple species. Osteoclast lineage cells from Mitf-mutant mice develop, but appear to arrest at approximately the fusion stage and exhibit profoundly defective bone resorption. This late developmental defect suggests that the Mitf transcription factor regulates late osteoclast differentiation genes, rather than global regulators of lineage determination. The identification of those genes and the transcriptional controls which modulate their expression stand to provide important new targets for the treatment of bone disorders in man. We observed that dominant negative alleles of Mitf produce severe osteopetrosis whereas null alleles do not. On this basis we identified TFE3, a related HLH factor, as a dimerization partner which shares transcriptional activities with Mitf in the osteoclast lineage. This overlapping role for Mitf and TFE3 has been verified in a double-null mouse model. We have also demonstrated that M-CSF, a vital cytokine for both early and late osteoclast development, triggers MAPK phosphorylation of both Mitf and TFE3 on a conserved serine, stimulating their recruitment of the coactivator p300. Mutation of this phosphoacceptor serine disrupts late osteoclastic differentiation. In addition to this post-translational regulation, we have identified several Mitf/TFE3 transcriptional target genes including the secreted protease cathepsin K, and the survival gene Bcl2. In vivo disruption of these genes results in osteopetrosis. The essential roles for Mitf/TFE3 specifically for late osteoclast maturation affords a unique opportunity to discover key pathways and mediators of the bone resorption process through the analysis of their biochemical regulation and target gene identification. We propose to carry out this analysis in two Specific Aims. The first focuses on elucidating transcriptional and post-translational mechanisms which regulate expression and activity of Mitf and TFE3, which in turn modulate late osteoclast development & bone resorption. The second represents a systematic approach to the identification of transcriptional targets of Mitf/TFE3 using screens which couple their biochemical activities to the signaling pathways in which they reside.
描述(由申请人提供):Mitf是一种螺旋-环-螺旋转录因子,其突变可在多个物种中产生严重的骨质疏松症。来自mitf突变小鼠的破骨细胞谱系细胞发育,但似乎在大约融合阶段停止,并表现出严重的骨吸收缺陷。这种晚期发育缺陷表明,Mitf转录因子调控晚期破骨细胞分化基因,而不是谱系决定的全局调控因子。这些基因的鉴定和调控其表达的转录控制将为人类骨疾病的治疗提供重要的新靶点。我们观察到Mitf的显性阴性等位基因产生严重的骨质疏松症,而无等位基因则不会。在此基础上,我们确定了TFE3,一个相关的HLH因子,作为一个二聚化伙伴,在破骨细胞谱系中与Mitf具有相同的转录活性。Mitf和TFE3的这种重叠作用已在双空小鼠模型中得到验证。我们还证明,M-CSF是早期和晚期破骨细胞发育的重要细胞因子,可触发MAPK在保守丝氨酸上的Mitf和TFE3磷酸化,刺激它们募集共激活因子p300。这种磷酸化受体丝氨酸的突变破坏了晚期破骨细胞的分化。除了这种翻译后调控外,我们还鉴定了几个Mitf/TFE3转录靶基因,包括分泌蛋白酶组织蛋白酶K和存活基因Bcl2。体内这些基因的破坏会导致骨质疏松。Mitf/TFE3在晚期破骨细胞成熟中的重要作用为通过分析其生化调控和靶基因鉴定发现骨吸收过程的关键途径和介质提供了独特的机会。我们建议在两个具体目标中进行这种分析。第一个重点是阐明调节Mitf和TFE3表达和活性的转录和翻译后机制,从而调节晚期破骨细胞的发育和骨吸收。第二种是一种系统的方法来识别Mitf/TFE3的转录靶标,使用筛选将其生化活性与它们所在的信号通路结合起来。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

DAVID E FISHER其他文献

DAVID E FISHER的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('DAVID E FISHER', 18)}}的其他基金

MITF from control of pigmentation to melanoma risk
MITF 从控制色素沉着到黑色素瘤风险
  • 批准号:
    10828041
  • 财政年份:
    2023
  • 资助金额:
    $ 29.92万
  • 项目类别:
A druggable dependency in low-MITF/high-AXL melanoma: preclinical efficacy and mechanism of action in a key treatment-resistant subclass.
低 MITF/高 AXL 黑色素瘤的药物依赖性:关键耐药亚类的临床前疗效和作用机制。
  • 批准号:
    10331800
  • 财政年份:
    2018
  • 资助金额:
    $ 29.92万
  • 项目类别:
Preclinical models and therapeutic strategies for treatment of giant congenital melanocytic nevi
先天性巨大黑素细胞痣的临床前模型及治疗策略
  • 批准号:
    9753925
  • 财政年份:
    2017
  • 资助金额:
    $ 29.92万
  • 项目类别:
Preclinical models and therapeutic strategies for treatment of giant congenital melanocytic nevi
先天性巨大黑素细胞痣的临床前模型及治疗策略
  • 批准号:
    9376481
  • 财政年份:
    2017
  • 资助金额:
    $ 29.92万
  • 项目类别:
Preclinical models and therapeutic strategies for treatment of giant congenital melanocytic nevi
先天性巨大黑素细胞痣的临床前模型及治疗策略
  • 批准号:
    10245261
  • 财政年份:
    2017
  • 资助金额:
    $ 29.92万
  • 项目类别:
Therapeutic strategies for treatment of giant congenital melanocytic nevi
巨大先天性黑素细胞痣的治疗策略
  • 批准号:
    10570507
  • 财政年份:
    2017
  • 资助金额:
    $ 29.92万
  • 项目类别:
Preclinical models and therapeutic strategies for treatment of giant congenital melanocytic nevi
先天性巨大黑素细胞痣的临床前模型及治疗策略
  • 批准号:
    9977915
  • 财政年份:
    2017
  • 资助金额:
    $ 29.92万
  • 项目类别:
Development of next-generation cancer functional diagnostics
下一代癌症功能诊断的开发
  • 批准号:
    8492572
  • 财政年份:
    2013
  • 资助金额:
    $ 29.92万
  • 项目类别:
Administrative Core
行政核心
  • 批准号:
    8415143
  • 财政年份:
    2013
  • 资助金额:
    $ 29.92万
  • 项目类别:
Project 1: Remodeling Chromatin and the Tumor Microenvironment: Direct Oncogenesis and Therapeutic Targeting
项目 1:重塑染色质和肿瘤微环境:直接肿瘤发生和治疗靶向
  • 批准号:
    10443720
  • 财政年份:
    2013
  • 资助金额:
    $ 29.92万
  • 项目类别:

相似海外基金

Wnt5a/Ror2 Signaling in Jaw Bone Development
颌骨发育中的 Wnt5a/Ror2 信号转导
  • 批准号:
    10730208
  • 财政年份:
    2023
  • 资助金额:
    $ 29.92万
  • 项目类别:
Impacts of parental benzo[a]pyrene exposure on offspring’s bone development
父母接触苯并[a]芘对后代骨骼发育的影响
  • 批准号:
    10658133
  • 财政年份:
    2023
  • 资助金额:
    $ 29.92万
  • 项目类别:
Wnt5a/Ror2 Signaling in Jaw Bone Development
颌骨发育中的 Wnt5a/Ror2 信号转导
  • 批准号:
    10545297
  • 财政年份:
    2022
  • 资助金额:
    $ 29.92万
  • 项目类别:
Tankyrase represses macrophage derived inflammatory cytokines and controls osteoclast activity during bone development.
端锚聚合酶抑制巨噬细胞衍生的炎症细胞因子并控制骨骼发育过程中的破骨细胞活性。
  • 批准号:
    469104
  • 财政年份:
    2022
  • 资助金额:
    $ 29.92万
  • 项目类别:
    Operating Grants
Impacts of parental benzo[a]pyrene exposure on offspring’s bone development
父母接触苯并[a]芘对后代骨骼发育的影响
  • 批准号:
    10203208
  • 财政年份:
    2021
  • 资助金额:
    $ 29.92万
  • 项目类别:
Wnt5a/Ror2 Signaling in Jaw Bone Development
颌骨发育中的 Wnt5a/Ror2 信号转导
  • 批准号:
    10353862
  • 财政年份:
    2021
  • 资助金额:
    $ 29.92万
  • 项目类别:
Acid-base regulation during bone development, homeostasis and metabolism
骨骼发育、体内平衡和代谢过程中的酸碱调节
  • 批准号:
    535680-2019
  • 财政年份:
    2021
  • 资助金额:
    $ 29.92万
  • 项目类别:
    Alexander Graham Bell Canada Graduate Scholarships - Doctoral
Wnt5a/Ror2 Signaling in Jaw Bone Development
颌骨发育中的 Wnt5a/Ror2 信号转导
  • 批准号:
    10669478
  • 财政年份:
    2021
  • 资助金额:
    $ 29.92万
  • 项目类别:
Quantitative characterization and predictive modeling of cranial bone development in patients with craniosynostosis
颅缝早闭患者颅骨发育的定量特征和预测模型
  • 批准号:
    10431946
  • 财政年份:
    2020
  • 资助金额:
    $ 29.92万
  • 项目类别:
Acid-base regulation during bone development, homeostasis and metabolism
骨骼发育、体内平衡和代谢过程中的酸碱调节
  • 批准号:
    535680-2019
  • 财政年份:
    2020
  • 资助金额:
    $ 29.92万
  • 项目类别:
    Postgraduate Scholarships - Doctoral
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了